RESUMO
The majority of tanning bed users in the U.S. are women. Previous health communication research frequently focused on the risk of skin cancer, but few studies assessed the mediated communication environment that may surround women's beliefs and behaviors relevant to tanning. A content analysis of articles in eight magazines targeting girls, young women, older women, and women who are interested in fitness during the ten-year period of 1997-2006 was conducted. The amount of coverage of tanning bed use consequences was less than 50% of the coverage of tanning benefits. About 40% of the tanning benefits coverage touted looking healthy. The coverage of prevention methods focused on sunscreen use (55%), while the more important methods (e.g., protective clothing use) were rarely featured. Longitudinally, the coverage of the risk and prevention relevant issues increased between 1997 and 2006. The data indicate that the coverage of tanning benefits also increased during the same period.
Assuntos
Publicações Periódicas como Assunto , Medição de Risco , Neoplasias Cutâneas/prevenção & controle , Banho de Sol , Adulto , Bibliometria , Feminino , Humanos , Neoplasias Cutâneas/diagnóstico , Estados Unidos , Adulto JovemAssuntos
Apoptose , Caspases/metabolismo , Desoxiadenosinas , Proteína Supressora de Tumor p53/genética , Proteína Supressora de Tumor p53/metabolismo , Androstadienos/farmacologia , Animais , Anexina A5/farmacologia , Anti-Inflamatórios não Esteroides/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Butiratos/farmacologia , Caspase 3 , Ciclo Celular , Linhagem Celular Tumoral , Corantes/farmacologia , Dano ao DNA , Desoxiadenosinas/farmacologia , Relação Dose-Resposta a Droga , Resistencia a Medicamentos Antineoplásicos , Ativação Enzimática , Inibidores Enzimáticos/farmacologia , Genisteína/farmacologia , Isoxazóis/farmacologia , Leflunomida , Camundongos , Modelos Biológicos , Purinas/farmacologia , RNA Mensageiro/metabolismo , Roscovitina , Sesquiterpenos/farmacologia , Fatores de Tempo , WortmaninaRESUMO
UNLABELLED: Hematopoietic stem cell (HSC) engraftment is delayed in children with hypersplenism, and splenectomy may improve HSC engraftment. However, the use of total splenectomy in children is limited because of concerns for postsplenectomy sepsis. In this study, the authors sought to assess the role of partial splenectomy for children with hypersplenism undergoing HSC transplantation. METHODS: Five children with a variety of conditions and associated hypersplenism underwent partial splenectomy before an HSC transplantation at the authors' institution between 2000 and 2003. Primary outcome measures were rates of neutrophil and platelet engraftment. Secondary outcome measures included perioperative complications, splenic regrowth, graft-versus-host disease, and infection rate. All outcomes were compared with recipients of an HSC transplant from both age-matched nonsplenectomized children (n = 497) and hypersplenic children who underwent total splenectomy (n = 10). Outcomes were compared using Wilcoxon's rank sum test. RESULTS: The rate of both neutrophil and platelet engraftment was faster in children who underwent either partial or total splenectomy as compared with nonsplenectomized children (mean rates of neutrophil engraftment were 26, 19, and 19 days for the nonsplenectomy, total splenectomy, and partial splenectomy groups, respectively; mean rates of platelet engraftment were 97, 37, and 45 days for the nonsplenectomy, total splenectomy, and partial splenectomy groups, respectively). Graft-versus-host disease rates were similar between the 3 groups. The mean percentage of splenic regrowth after partial splenectomy was 39%. There were no perioperative complications. CONCLUSIONS: Partial splenectomy may be safely performed before HSC transplantation and, similar to total splenectomy, may improve the rate of HSC engraftment. Although this series has a limited number of patients, the use of partial splenectomy appears to be safe and may allow for splenic salvage to minimize the risk of postsplenectomy sepsis.
Assuntos
Doenças Hematológicas/cirurgia , Transplante de Células-Tronco Hematopoéticas , Hiperesplenismo/cirurgia , Síndromes de Imunodeficiência/cirurgia , Esplenectomia , Criança , Pré-Escolar , Feminino , Sobrevivência de Enxerto , Doenças Hematológicas/complicações , Humanos , Hiperesplenismo/complicações , Síndromes de Imunodeficiência/complicações , Masculino , Cuidados Pré-Operatórios , Resultado do TratamentoRESUMO
Cutaneous melanoma remains an ongoing public health threat, and the cornerstone of management continues to be early diagnosis and treatment. Unfortunately, primary melanomas may have atypical presentations, making early diagnosis difficult and causing significant treatment delays. In this report, an unusual case is presented in which a patient experienced the synchronous development of a melanoma in situ within a skin graft donor site and an invasive melanoma within the recipient skin graft site. This exceptional presentation of cutaneous melanoma is discussed to highlight key principles of skin grafting in relation to the management of malignant melanoma.
Assuntos
Fasciotomia , Melanoma/etiologia , Inoculação de Neoplasia , Neoplasias Cutâneas/etiologia , Transplante de Pele/efeitos adversos , Traumatismos em Atletas/complicações , Síndromes Compartimentais/etiologia , Síndromes Compartimentais/cirurgia , Humanos , Masculino , Melanoma/cirurgia , Pessoa de Meia-Idade , Neoplasias Cutâneas/cirurgia , Procedimentos Cirúrgicos Operatórios/efeitos adversos , Fraturas da Tíbia/etiologia , Fraturas da Tíbia/cirurgia , Ferimentos e Lesões/etiologia , Ferimentos e Lesões/cirurgiaRESUMO
BACKGROUND: beta-thalassemia major, one of the most prevalent hemoglobinopathies throughout the world, can be cured by allogeneic stem cell transplantation therapy. Many patients, however, lack a suitably matched related donor. Unrelated umbilical cord blood can be used as an alternative stem cell source for some of these patients. This report describes the successful transplantation of a 2-month-old infant with beta-thalassemia major using partially HLA-matched unrelated umbilical cord blood. METHODS: After cytoreduction with busulfan, cyclophosphamide, and antithymocyte globulin (ATG), the patient underwent transplantation at the age of 2 months with a 4/6 HLA matching umbilical cord blood unit from an unrelated donor. RESULTS: The patient engrafted promptly with 100% donor chimerism. His only major complication was an autoimmune hemolytic anemia that resolved 2 years after transplantation. He is currently surviving, event-free, 5 years after transplantation with normal growth and cognitive development and full donor chimerism without evidence of beta-thalassemia. CONCLUSIONS: Umbilical cord blood transplantation from related and unrelated donors should be considered for patients with beta-thalassemia major who lack traditional bone marrow donors. As most newborns undergo screening for hemoglobinopathies, those with disease could be transplanted early in life before experiencing the morbidity and mortality caused by transfusion therapy, alloimmunization, and iron overload, increasing the likelihood of successful transplantation therapy.